# Study of the Ameliorative Effect of Naltrexone/Bupropion, Liraglutide or Food Restriction On $\beta$ -Cell Regeneration and Insulin Resistance in Obese Diabetic Male Albino Rats

# Thesis

Submitted for Partial Fulfilment of the Requirement of the Master Degree in Physiology (Basic medical sciences)

### By

Reem Ahmed Omar Hammad

(M. B, B. Ch.)

## Under supervision of

Prof. Dr. Amani Mohamed El-Amin Ali

Professor of Medical Physiology and Head of Physiology Department Faculty of Medicine, Fayoum University

# Dr. Ahmed Magdy Abdel Rahman El Ebiary

Lecturer of Medical Physiology Faculty of Medicine, Fayoum University

### Dr. Dina Hamdy Mohamed Merzeban

Lecturer of Medical Physiology Faculty of Medicine, Fayoum University

# Faculty of Medicine – Fayoum University 2024

### ABSTRACT

Background: insulin resistance, characterized by impaired cellular response to insulin, plays a central role in the development of type 2 diabetes mellitus and obesity.

Aim of work: The aim of this work is to assess the effects of naltrexone/bupropion on body weight,  $\beta$ -cell regeneration, cardiovascular outcomes and the mechanism by which they can affect some selected parameters. Also, to compare the effect of naltrexone/bupropion on these parameters with both caloric restriction and liraglutide in obese type 2 diabetic male albino rats.

Methodology: This study is a comparative study which was conducted in the animal house of faculty of medicine, Fayoum university, Egypt. It

### الدراسات العليا

### 2

included 50 male albino rats who were divided into 5 groups; group I: normal control group in which rats continued on standard commercial chow diet, group II: obese diabetic control group, group III: caloric restricted group in which rats subjected to dietary restriction of about 50% of the food intake of normal control group, group IV: (NTX+BUP) treated group (by a ratio of 1 NTX / 10 BUP, orally) and group V: liraglutide treated group (0.3mg/kg/day, S.C). Body weight, blood pressure, fasting glucose, fasting insulin,  $\beta$ -arrestin-1 were measured. Body mass index (BMI), homeostatic model assessment of insulin resistance (HOMA-IR) and of beta-cell function (HOMA- $\beta$ ) were calculated. Hematoxylin and eosin (H&E), anti-insulin antibodies and Ki-67 staining for histopathology of the pancreas was done.

Results: The results demonstrated significant improvement in insulin resistance, serum lipid profile and systolic blood pressure across all intervention groups compared to obese diabetic control group (P<0.05). Weight reduction was significantly higher in treatment with (NTX+BUP) treated group than liraglutide treated group and insignificantly higher than caloric restriction group.  $\beta$ -cell regeneration (assed through Ki-67 and anti-insulin Abs) was significantly higher in liraglutide treatment than caloric restriction and (NTX+BUP) treated groups however caloric restriction group was significantly higher than (NTX+BUP) treated group regarding  $\beta$ -cell regeneration. There were no statistically significant differences between treated groups according serum insulin level, serum lipid profile, HOMA-IR, HOMA- $\beta$ , systolic blood pressure, diastolic blood pressure and mean arterial blood pressure (MAP) or atherogenic indices. There was no significant correlation between  $\beta$ -arrestin-1 and serum glucose, serum insulin, HOMA-IR or HOMA- $\beta$ . There was a positive correlation between MAP and atherogenic index of plasma (AIP). Conclusion: our study highlights the potential benefits of (NTX+BUP), liraglutide and caloric restriction in ameliorating insulin resistance and

الدراسات العليا

promoting weight loss in diabetic obese male albino rats. Furthermore, (NTX+BUP) promising effect on glycemic control and systolic blood pressure reduction suggesting potential therapeutic approach for weight reduction in obese hypertensive diabetic patients but its role in  $\beta$ -cell regeneration was minor.

Keywords: Naltrexone/Bupropion, Liraglutide, Caloric restriction,  $\beta$ -cell regeneration, Obesity, Type 2 diabetes, Rats.